Published in Value Health on March 24, 2016
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology (2013) 12.46
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep (2012) 6.91
Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med (2011) 6.69
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care (2008) 5.14
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making (1985) 4.47
Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care (1998) 4.04
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Projecting future complications of chronic hepatitis C in the United States. Liver Transpl (2003) 3.84
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med (2014) 3.50
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology (2014) 3.28
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol (2013) 2.87
Hepatitis C in the United States. N Engl J Med (2013) 2.63
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology (2014) 2.32
Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology (2014) 2.17
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
United States life tables, 2009. Natl Vital Stat Rep (2014) 1.89
The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol (2008) 1.77
Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep (2015) 1.69
Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl (2010) 1.69
Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol (2004) 1.68
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med (2015) 1.61
All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis (2011) 1.60
Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage. Dig Dis Sci (2015) 1.59
Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther (2010) 1.51
OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant (2013) 1.48
Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant (2010) 1.47
All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm (2011) 1.44
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33
Effect of hepatitis C virus and its treatment on survival. Hepatology (2009) 1.20
Therapy of hepatitis C--back to the future. N Engl J Med (2014) 1.17
Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol (2005) 1.08
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology (2015) 1.04
A cure for the high cost of hepatitis C virus treatment. Ann Intern Med (2015) 0.90
All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci (2014) 0.86
A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C. Med Lett Drugs Ther (2014) 0.85
Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase. Health Aff (Millwood) (2014) 0.82
OPTN/SRTR 2013 Annual Data Report: economics. Am J Transplant (2015) 0.80
A 4-drug combination (Viekira Pak) for hepatitis C. Med Lett Drugs Ther (2015) 0.79
Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology (2015) 0.79
The ongoing debate of who to treat for chronic hepatitis C virus. JAMA Intern Med (2015) 0.77
Treatment strategy for hepatitis C: a dilemma for the payers and the providers. Am J Gastroenterol (2014) 0.76